ProQR Therapeutics files prospectus for resale of up to 3,030,303 shares

ProQR Therapeutics N.V. filed a prospectus dated July 15, 2026 covering the potential resale of up to an aggregate of 3,030,303 ordinary shares, nominal value €0.04 per share, by a selling shareholder identified elsewhere in the prospectus.¹ The shares were issued to the selling shareholder pursuant to a Share Purchase Agreement dated April 7, 2026, entered into as part of a private placement involving the selling shareholder.¹

The filing is a resale registration rather than a new capital raise. ProQR is not selling any of the shares under this prospectus and will not receive any proceeds from the sale or other disposition of the shares by the selling shareholder.¹ The company said it has agreed to bear all expenses incurred in connection with the registration of the shares, other than fees and expenses of counsel or other advisors to Ginkgo or underwriting discounts, brokerage fees and commissions incurred by Ginkgo, if any, in connection with the sale of the shares.¹

The prospectus does not state elsewhere that Ginkgo Bioworks is the selling shareholder in this offering; that name appears only in the expense-allocation language above and separately in connection with a research partnership. ProQR has established a partnership with Ginkgo Bioworks and formed an AI Advisory Board comprised of external experts in artificial intelligence and machine learning¹ as part of its Axiomer RNA-editing platform work.

Shares can be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, on the over-the-counter market, in privately negotiated transactions, or using a combination of these methods, at fixed prices, at prevailing market prices, or at privately negotiated prices.¹ ProQR ordinary shares trade on Nasdaq under "PRQR," and on July 2, 2026, the last reported sale price was $1.81 per share.¹